Frontlight ResearchEarly access
Taking people in JapanNo phase
Long-term safety survey of AJOVY injection for migraine in routine use
Observes long-term safety of fremanezumab injection in adults with migraine.
Key facts
- Who runs it
- Otsuka Pharmaceutical Co., Ltd.
- Where
- Osaka, JapanSee the site
- Trial code
- Registry title
- Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 20 Apr 2022
- Expected to end
- 22 Jun 2029
- Type of study
- Observational
- Treatments tested
- Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- Record updated
- 22 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who use AJOVY (fremanezumab) injections, to follow long-term safety in real-life use.
- Age
- 18 years and older
- Sex
- All sexes can join.
Main reasons for not taking part
- Known hypersensitivity (allergy) to components of AJOVY
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- -
Who cannot take part
- patients with a known hypersensitivity to components of AJOVY
Where in Japan
- Pharmacovigilance DepartmentOsaka, JapanContact: Satoshi Komaniwa, PhDTaking people
About the trial
What the trial wants to find out
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
The group in the trial
- Drug
Ajovy syringe for SC injection 225 mg.
Treatment: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
- Plain-language title
- Long-term safety survey of AJOVY injection for migraine in routine useGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 June 2026